Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge

References

• https://covid19.who.int.
   Google Scholar
• https://www.cdc.gov/coronavirus/2019-ncov/science/data-review/risk.html.
   Google Scholar
• https://www.cdc.gov/coronavirus/2019-ncov/science/data-review/vaccines.html.
   Google Scholar
• COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed September 2022.
   Google Scholar
• Bassetti M, Giacobbe DR, Bruzzi P, et al. Clinical management of adult patients with COVID-19 Outside intensive care units: guidelines from the italian society of Anti-Infective therapy (SITA) and the Italian Society of Pulmonology (SIP). Infect Dis Ther. 2021;10(4):1837–1885. doi: 10.1007/s40121-021-00487-7.
   PubMed Web of Science ®Google Scholar
• Deng J, Heybati K, Ramaraju HB, et al. Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis. Infection 2023;51(1):21–35. doi: 10.1007/s15010-022-01825-8.
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals. Regeneron’s REGEN-COV2 is first antibody cocktail for COVID-19 to receive FDA emergency use authorization [media release]. 21 Nov 2020. http://www.regen eron.com.
   Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021;384(3):238–251. doi: 10.1056/NEJMoa2035002.
   PubMed Web of Science ®Google Scholar
• Portal-Celhay C, Forleo-Neto E, Eagan W, et al. Virologic efficacy of casirivimab and imdevimab COVID-19 antibody combination in outpatients with SARS-CoV-2 infection: a phase 2 dose-ranging randomized clinical trial. JAMA Netw Open. 2022;5(8):e2225411. doi: 10.1001/jamanetworkopen.2022.25411.
   PubMed Web of Science ®Google Scholar
• Nomura T, Kitagawa H, Kakimoto M, et al. Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2. J Infect Chemother. 2022;28(7):912–917. doi: 10.1016/j.jiac.2022.03.013.
   PubMed Web of Science ®Google Scholar
• Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021;374:n2231. doi: 10.1136/bmj.n2231.
   PubMed Web of Science ®Google Scholar
• Hayek S, Ben-Shlomo Y, Dagan N, et al. Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes. Nat Commun. 2022;13(1):4480. doi: 10.1038/s41467-022-32253-9.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236–1246. doi: 10.1001/jama.2022.2832.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950. doi: 10.1056/NEJMoa2107934.
   PubMed Web of Science ®Google Scholar
• Kreuzberger N, Hirsch C, Chai KL, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Haematology Group, editor. Cochrane Database of Systematic Reviews. 2021 Sep 2 [cited 2022 Sep 18]; 2021(9). Available from: https://doi.org/10.1002/14651858.CD013825.pub2
   Google Scholar
• Huang DT, McCreary EK, Bariola JR, et al. Effectiveness of casirivimab-imdevimab and sotrovimab During a SARS-CoV-2 Delta variant surge: a cohort study and randomized comparative effectiveness trial. JAMA Netw Open. 2022;5(7):e2220957. doi: 10.1001/jamanetworkopen.2022.20957.
   PubMed Web of Science ®Google Scholar
• Razonable RR, O'Horo JC, Challener DW, et al. Curbing the delta surge: clinical outcomes after treatment with bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab for mild to moderate coronavirus disease 2019. Mayo Clin Proc. 2022;97(9):1641–1648. doi: 10.1016/j.mayocp.2022.06.015.
   PubMed Web of Science ®Google Scholar
• Lafont E, Pere H, Lebeaux D, et al. Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19. J Antimicrob Chemother. 2022;77(10):2688–2692.
   PubMed Web of Science ®Google Scholar
• Birk NK, Jain S, Massoud L, et al. Real-world experience of sotrovimab in high-risk, immunocompromised COVID-19 patients. Open Forum Infect Dis. 2022;9(7):ofac282.
   PubMed Web of Science ®Google Scholar
• Ganesh R, Philpot LM, Bierle DM, et al. Real-World clinical outcomes of bamlanivimab and casirivimab-imdevimab Among high-risk patients With mild to moderate coronavirus disease 2019. J Infect Dis. 2021;224(8):1278–1286. doi: 10.1093/infdis/jiab377.
   PubMed Web of Science ®Google Scholar
• Sarrell BA, Bloch K, El Chediak A, et al. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients. Transpl Infect Dis. 2022;24(1):e13759.
   PubMed Web of Science ®Google Scholar
• Verderese JP, Stepanova M, Lam B, et al. Neutralizing monoclonal antibody treatment reduces hospitalization for mild and moderate coronavirus disease 2019 (COVID-19): a real-World experience. Clin Infect Dis. 2022;74(6):1063–1069. doi: 10.1093/cid/ciab579.
   PubMed Web of Science ®Google Scholar
• Piccicacco N, Zeitler K, Ing A, et al. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the omicron surge. J Antimicrob Chemother. 2022;77(10):2693–2700.
   PubMed Web of Science ®Google Scholar
• Shrestha LB, Foster C, Rawlinson W, et al. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol. 2022;32(5):e2381. doi: 10.1002/rmv.2381.
   PubMed Web of Science ®Google Scholar
• Zhou H, Dcosta BM, Landau NR, et al. Resistance of SARS-CoV-2 omicron BA.1 and BA.2 variants to vaccine-Elicited sera and therapeutic monoclonal antibodies. Viruses. 2022;14(6):1334. doi: 10.3390/v14061334.
   PubMed Web of Science ®Google Scholar
• Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against covid-19 omicron variant. N Engl J Med. 2022;386(10):995–998. doi: 10.1056/NEJMc2119407.
   PubMed Web of Science ®Google Scholar
• Yamasoba D, Kosugi Y, Kimura I, et al. Sensitivity of novel SARS-CoV-2 omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies. Microbiology. 2022 May [cited 2022 Nov 29]. Available from: http://biorxiv.org/lookup/doi/10.1101/2022.05.03.490409
   Google Scholar
• Kadowaki T, Imajou S, Matsumoto N, et al. Timing of REGEN-COV administration and progression to severe COVID-19. J Infect Chemother. 2022;28(11):1459–1463. doi: 10.1016/j.jiac.2022.07.002.
   PubMed Web of Science ®Google Scholar
• Mazzaferri F, Mirandola M, Savoldi A, et al. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 omicron variant of concern. Elife. 2022;11:e79639. doi: 10.7554/eLife.79639.
   PubMed Web of Science ®Google Scholar
• Mazzitelli M, Trunfio M, Sasset L, et al. Risk of hospitalization and sequelae in patients with COVID‐19 treated with 3‐day early remdesivir vs. controls in the vaccine and omicron era: a real‐life cohort study. J Med Virol. 2023;95(3):e28660. doi: 10.1002/jmv.28660.
   PubMed Web of Science ®Google Scholar
• Basoulis D, Tsakanikas A, Gkoufa A, et al. Effectiveness of oral nirmatrelvir/ritonavir vs. intravenous three-day remdesivir in preventing progression to severe COVID-19: a Single-Center, prospective, comparative, real-life study. Viruses. 2023;15(7):1515. doi: 10.3390/v15071515.
   PubMed Web of Science ®Google Scholar
• Mazzitelli M, Mengato D, Sasset L, et al. Molnupiravir and nirmatrelvir/ritonavir: tolerability, safety, and adherence in a retrospective cohort study. Viruses. 2023;15(2):384. doi: 10.3390/v15020384.
   PubMed Web of Science ®Google Scholar
• Tiseo G, Barbieri C, Galfo V, et al. Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a real-World cohort of outpatients with COVID-19 at high risk of progression: the PISA outpatient clinic experience. Infect Dis Ther. 2023;12(1):257–271. doi: 10.1007/s40121-022-00729-2.
   PubMed Web of Science ®Google Scholar
• Mutoh Y, Umemura T, Nishikawa T, et al. Real-World experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir/ritonavir in high-risk patients with COVID-19 in a community setting. Viruses. 2023;15(3):811. doi: 10.3390/v15030811.
   PubMed Web of Science ®Google Scholar
• Martin-Blondel G, Marcelin AG, Soulié C, et al. Outcome of very high-risk patients treated by sotrovimab for mild-to-moderate COVID-19 omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). J Infect. 2022;84(6):e101–4–e104. doi: 10.1016/j.jinf.2022.04.010.
   Web of Science ®Google Scholar
• Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19. N Engl J Med. 2021;384(3):229–237. doi: 10.1056/NEJMoa2029849.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382–393. doi: 10.1038/s41577-021-00542-x.
   PubMed Web of Science ®Google Scholar
• O'Brien MP, Forleo-Neto E, Sarkar N, et al. Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial. JAMA. 2022;327(5):432–441. doi: 10.1001/jama.2021.24939.
   PubMed Web of Science ®Google Scholar
• Li D, Sempowski GD, Saunders KO, et al. SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment. Annu Rev Med. 2022;73(1):1–16. doi: 10.1146/annurev-med-042420-113838.
   PubMedGoogle Scholar
• Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045.e9. doi: 10.1016/j.cell.2020.04.026.
   PubMed Web of Science ®Google Scholar
• Wrenn JO, Pakala SB, Vestal G, et al. COVID‐19 severity from omicron and delta SARS‐CoV‐2 variants. Influenza Other Respir Viruses. 2022;16(5):832–836. doi: 10.1111/irv.12982.
   PubMed Web of Science ®Google Scholar
• Fan G, Song H, Yip S, et al. Impact of low vaccine coverage on the resurgence of COVID-19 in Central and Eastern Europe. One Health. 2022;14:100402. doi: 10.1016/j.onehlt.2022.100402.
   PubMed Web of Science ®Google Scholar